vs
ZoomInfo Technologies Inc.（GTM）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
ZoomInfo Technologies Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$319.1M vs $207.3M），ZoomInfo Technologies Inc.净利率更高（10.9% vs -62.0%，领先72.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.2%），ZoomInfo Technologies Inc.自由现金流更多（$127.1M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 1.4%）
ZoomInfo Technologies Inc.是美国合规注册的数据服务商，通过数据采集、网页抓取等多元渠道汇总公开及非公开个人数据，同时收集企业、部门等商业主体信息，面向企业客户提供相关数据产品，助力客户开展精准营销等业务活动。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GTM vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $319.1M | $207.3M |
| 净利润 | $34.7M | $-128.6M |
| 毛利率 | 84.0% | — |
| 营业利润率 | 17.0% | -54.7% |
| 净利率 | 10.9% | -62.0% |
| 营收同比 | 3.2% | 25.9% |
| 净利润同比 | 137.7% | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $319.1M | $207.3M | ||
| Q3 25 | $318.0M | $159.9M | ||
| Q2 25 | $306.7M | $166.5M | ||
| Q1 25 | $305.7M | $139.3M | ||
| Q4 24 | $309.1M | $164.6M | ||
| Q3 24 | $303.6M | $139.5M | ||
| Q2 24 | $291.5M | $147.0M | ||
| Q1 24 | $310.1M | $108.8M |
| Q4 25 | $34.7M | $-128.6M | ||
| Q3 25 | $38.7M | $-180.4M | ||
| Q2 25 | $24.0M | $-115.0M | ||
| Q1 25 | $26.8M | $-151.1M | ||
| Q4 24 | $14.6M | $-133.2M | ||
| Q3 24 | $23.8M | $-133.5M | ||
| Q2 24 | $-24.4M | $-131.6M | ||
| Q1 24 | $15.1M | $-170.7M |
| Q4 25 | 84.0% | — | ||
| Q3 25 | 83.7% | — | ||
| Q2 25 | 83.9% | — | ||
| Q1 25 | 84.5% | — | ||
| Q4 24 | 82.8% | — | ||
| Q3 24 | 84.4% | — | ||
| Q2 24 | 84.3% | — | ||
| Q1 24 | 86.0% | — |
| Q4 25 | 17.0% | -54.7% | ||
| Q3 25 | 21.2% | -106.9% | ||
| Q2 25 | 17.5% | -64.8% | ||
| Q1 25 | 16.5% | -102.6% | ||
| Q4 24 | 10.0% | -74.3% | ||
| Q3 24 | 14.3% | -94.6% | ||
| Q2 24 | -6.9% | -79.1% | ||
| Q1 24 | 13.9% | -151.9% |
| Q4 25 | 10.9% | -62.0% | ||
| Q3 25 | 12.2% | -112.8% | ||
| Q2 25 | 7.8% | -69.0% | ||
| Q1 25 | 8.8% | -108.5% | ||
| Q4 24 | 4.7% | -80.9% | ||
| Q3 24 | 7.8% | -95.7% | ||
| Q2 24 | -8.4% | -89.5% | ||
| Q1 24 | 4.9% | -156.8% |
| Q4 25 | $0.11 | $-1.28 | ||
| Q3 25 | $0.12 | $-1.81 | ||
| Q2 25 | $0.07 | $-1.17 | ||
| Q1 25 | $0.08 | $-1.57 | ||
| Q4 24 | $0.04 | $-1.34 | ||
| Q3 24 | $0.07 | $-1.40 | ||
| Q2 24 | $-0.07 | $-1.52 | ||
| Q1 24 | $0.04 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $179.9M | $421.0M |
| 总债务越低越好 | $1.3B | — |
| 股东权益账面价值 | $1.5B | $-80.0M |
| 总资产 | $6.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.88× | — |
8季度趋势，按日历期对齐
| Q4 25 | $179.9M | $421.0M | ||
| Q3 25 | $135.0M | $202.5M | ||
| Q2 25 | $176.9M | $176.3M | ||
| Q1 25 | $140.5M | $127.1M | ||
| Q4 24 | $139.9M | $174.0M | ||
| Q3 24 | $147.7M | $150.6M | ||
| Q2 24 | $399.3M | $480.7M | ||
| Q1 24 | $440.2M | $112.3M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.5B | $-80.0M | ||
| Q3 25 | $1.5B | $9.2M | ||
| Q2 25 | $1.6B | $151.3M | ||
| Q1 25 | $1.6B | $144.2M | ||
| Q4 24 | $1.7B | $255.0M | ||
| Q3 24 | $1.7B | $346.8M | ||
| Q2 24 | $1.9B | $432.4M | ||
| Q1 24 | $2.0B | $140.3M |
| Q4 25 | $6.4B | $1.5B | ||
| Q3 25 | $6.4B | $1.2B | ||
| Q2 25 | $6.5B | $1.3B | ||
| Q1 25 | $6.4B | $1.3B | ||
| Q4 24 | $6.5B | $1.5B | ||
| Q3 24 | $6.4B | $1.5B | ||
| Q2 24 | $6.7B | $1.6B | ||
| Q1 24 | $6.8B | $1.3B |
| Q4 25 | 0.88× | — | ||
| Q3 25 | 0.87× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.66× | — | ||
| Q1 24 | 0.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $143.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $127.1M | $-100.8M |
| 自由现金流率自由现金流/营收 | 39.8% | -48.6% |
| 资本支出强度资本支出/营收 | 5.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.14× | — |
| 过去12个月自由现金流最近4个季度 | $389.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $143.5M | $-99.8M | ||
| Q3 25 | $93.8M | $-91.4M | ||
| Q2 25 | $108.9M | $-108.3M | ||
| Q1 25 | $119.2M | $-166.5M | ||
| Q4 24 | $109.0M | $-79.3M | ||
| Q3 24 | $18.2M | $-67.0M | ||
| Q2 24 | $126.3M | $-77.0M | ||
| Q1 24 | $115.9M | $-190.7M |
| Q4 25 | $127.1M | $-100.8M | ||
| Q3 25 | $70.9M | $-92.7M | ||
| Q2 25 | $86.9M | $-110.7M | ||
| Q1 25 | $104.4M | $-167.8M | ||
| Q4 24 | $85.6M | $-79.5M | ||
| Q3 24 | $600.0K | $-68.6M | ||
| Q2 24 | $115.2M | $-79.0M | ||
| Q1 24 | $103.1M | $-193.9M |
| Q4 25 | 39.8% | -48.6% | ||
| Q3 25 | 22.3% | -58.0% | ||
| Q2 25 | 28.3% | -66.5% | ||
| Q1 25 | 34.2% | -120.5% | ||
| Q4 24 | 27.7% | -48.3% | ||
| Q3 24 | 0.2% | -49.2% | ||
| Q2 24 | 39.5% | -53.7% | ||
| Q1 24 | 33.2% | -178.2% |
| Q4 25 | 5.1% | 0.5% | ||
| Q3 25 | 7.2% | 0.8% | ||
| Q2 25 | 7.2% | 1.5% | ||
| Q1 25 | 4.8% | 1.0% | ||
| Q4 24 | 7.6% | 0.1% | ||
| Q3 24 | 5.8% | 1.2% | ||
| Q2 24 | 3.8% | 1.4% | ||
| Q1 24 | 4.1% | 3.0% |
| Q4 25 | 4.14× | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 4.45× | — | ||
| Q4 24 | 7.47× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 7.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTM
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
